Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy-Reference-Cited by-同舟云学术

Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy

Published:2008-11 Issue:2 Volume:129 Page:219-229
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Zhang Lei,Dermawan Kamtai,Jin Meilin,Liu Rongjun,Zheng Huiru,Xu Lin,Zhang Yi,Cai Yuchan,Chu Yiwei,Xiong Sidong

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference49 articles.

1. Paclitaxel (Taxol);Rowinsky;N. Engl. J. Med.,1995

2. The antineoplastic drug paclitaxel has immunosuppressive properties that can effectively promote allograft survival in a rat heart transplant model;Tange;Transplantation,2002

3. Bcl-2 mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription;Srivastava;J. Exp. Med.,1999

4. Paclitaxel induces apoptosis in Saos-2 cells with CD95L upregulation and Bcl-2 phosphorylation;Pucci;Exp. Cell Res.,1999

5. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer;Yu;Clin. Cancer Res.,2003

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemotherapy-induced peripheral neuropathy biomarkers: current updates, challenges, and potentials;The Egyptian Journal of Neurology, Psychiatry and Neurosurgery;2024-08-06

2. The future of cancer treatment: combining radiotherapy with immunotherapy;Frontiers in Molecular Biosciences;2024-07-09

3. Chemotherapy-induced high expression of IL23A enhances efficacy of anti-PD-1 therapy in TNBC by co-activating the PI3K-AKT signaling pathway of CTLs;Scientific Reports;2024-06-20

4. A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody;ESMO Open;2024-06

5. The use of T-cells with chimeric antigen receptor (CAR-T) in combination with chemotherapy and radiotherapy for the treatment of solid tumors;Advances in Molecular Oncology;2024-04-05